Edwards Lifesciences has received conditional investigational device exemption approval from the FDA to enroll as many as 500 inoperable and high-risk aortic stenosis patients in a clinical study of its Sapien 3 transcatheter aortic valve implantation device. The next-generation device improves on the older versions with advanced delivery systems, a lower profile and other features, a company official said.

Related Summaries